Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Echelon Hungry for .WT Warrants Today
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1102)
•••
Comment by capebretongirlon Apr 09, 2021 3:07pm
99 Views
Post# 32968115

RE:RE:RE:RE:Echelon Hungry for .WT Warrants Today

RE:RE:RE:RE:Echelon Hungry for .WT Warrants Today
gojotv! wrote: You're plenty stupid, aren't you, Marcus?
The WT price only goes up if the share price goes up, so why didn't Echelon buy shares?
It's because they see the bigger future potential of exercising warrants... And for far less immediate cash outlay, meaning they can access more shares in the future with less cash today.
Duh!


Marcus358 wrote: don't you think echelon will convert this warrants to share......whi will convert now?  lol.....he will sell it as a warrant...if he buy at .05 and sell at .06 thasts a 20% gain......
gojotv! wrote: That's interesting, because it takes eight (8) SZLS.WTs to convert to one SZLS share at $0.72.
And the WTs are now selling at $0.05, or $0.40/share...
For a total of $1.12 outlay per share...
Gives you an idea of what Echelon thinks of this stock...!
GLTA!

Str8Shuter wrote:
Buying up SZLS.WT by the many hundreds of thousands. 

It will be interesting to see today's trading house positions, if anyone can share their view of the stats.  Perhaps now, and again after the close of the market.  Thanks in advance!

 

 

This explanation falls on deft ears in Marcus' case.  Unless you have a coloring book and crayons ready, there really is no chance.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities